Affimed turns its back on T-cell recruitment
The German group’s decision to switch focus to innate immunity had been on the cards since a deal with Roche last August.
Hard knocks for brain cancer, again
In the wake of two phase III glioblastoma failures this month, from Abbvie and Bristol-Myers Squibb, hopes dim for another big readout from Tocagen.
Colorectal cancer could see Array stand alone at last
The group’s Braftovi/Mektovi combo shows the potential of a targeted approach in colorectal cancer, so where is the competition?
Abbott shifts to tricuspid repair
First-look data on Abbott’s tricuspid-focused MitraClip follow-on device are promising, but can TriClip emulate its predecessor’s success?
Merck sees potential in Peloton
Peloton Therapeutics’ approach to fighting kidney tumours has apparently convinced Merck & Co, which is to pay $1.05bn for the company on the back of relatively…
Aegerion’s poisoned chalice gives Amryt some distraction therapy
Three years after being merged with QLT the Aegerion business is to be sold out of bankruptcy protection.
A delicate balancing act for Immunogen
The group is desperately playing up mirvetuximab, but its future rests with a pair of earlier-stage projects.
Asco 2019 – Guardant and Grail square up
Two closely-watched liquid biopsy developers are to present data on their respective solid tumour blood tests.
A tale of two eyes as Meiragtx sees a clearer path forward than Gensight
As Meiragtx wows investors with its gene therapy for a cause of blindness, continuing lack of clarity around Gensight’s GS010 prompts more questions than answers.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.